Cargando…

O4.2. THE PREVENTION OF RELAPSE AND HOSPITALIZATION IN FIRST EPISODE AND EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE PRELAPSE TRIAL

BACKGROUND: Even with early intervention services, a third or more of first-episode patients are hospitalized over the first 2 yrs. of treatment. Non-adherence is a major factor in increasing risk of hospitalization. Long-acting injectable antipsychotics (LAI’s) have shown effectiveness in addressin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kane, John, Robinson, Delbert, Schooler, Nina, Marcy, Patricia, Achtyes, Eric, Correll, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Oral Session: Digital Health/Methods
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234050/ http://dx.doi.org/10.1093/schbul/sbaa028.019

Ejemplares similares

O9.7. TECHNOLOGY ASSISTED RELAPSE PREVENTION PROGRAM REDUCES HOSPITALIZATION IN SCHIZOPHRENIA PATIENTS AT HIGH RISK FOR RELAPSE
por: Schooler, Nina, et al.
Publicado: (2020)

O4.5. LONG TERM EFFECTS OF EARLY INTERVENTION SERVICES FOR FIRST EPISODE PSYCHOSIS: OUTCOMES OVER FIVE YEARS FROM THE RECOVERY AFTER A 1ST EPISODE OF SCHIZOPHRENIA-EARLY TREATMENT PROGRAM (RAISE-ETP)
por: Robinson, Delbert, et al.
Publicado: (2020)

O4.1. AEROBIC EXERCISE DOSE DETERMINES THE COGNITIVE GAIN IN FIRST-EPISODE SCHIZOPHRENIA, SO HOW DO WE ENCOURAGE SUFFICIENT EXERCISE?
por: Nuechterlein, Keith, et al.
Publicado: (2020)

O2.2. EVALUATION OF THE RELATIONSHIP BETWEEN GLUTAMATE AND BRAIN CONNECTIVITY IN ANTIPSYCHOTIC-NAïVE FIRST EPISODE PATIENTS – A COMBINED MAGNETIC RESONANCE SPECTROSCOPY AND RESTING STATE FUNCTIONAL CONNECTIVITY MRI STUDY
por: Maximo, Jose, et al.
Publicado: (2020)

O11.4. INTERACTOME OVERLAP BETWEEN SCHIZOPHRENIA AND COGNITION
por: Koch, Elise, et al.
Publicado: (2020)

O6.1. COGNITIVE CONTROL DIFFERENCES BETWEEN TREATMENT RESPONSIVE AND TREATMENT RESISTANT FIRST-EPISODE PSYCHOSIS PATIENTS
Publicado: (2020)

O11.2. ELEVATION OF MACROPHAGE-RELATED TRANSCRIPTS IN THE MIDBRAIN IN SCHIZOPHRENIA
por: Purves-Tyson, Tertia, et al.
Publicado: (2020)

O5.3. IMPAIRED LEFT TEMPORAL-PARIETAL JUNCTION FMRI ACTIVITY DURING CATEGORY FLUENCY IN FIRST-EPISODE PSYCHOSIS
por: Perumaly, Leana, et al.
Publicado: (2020)

O3.5. EARLY TRAJECTORIES OF POSITIVE SYMPTOMS REMISSION IN FIRST EPISODE-PSYCHOSIS: A 2-YEAR FOLLOW-UP STUDY
por: Percie du Sert, Olivier, et al.
Publicado: (2020)

O2.4. FUNCTIONAL CONNECTOME-WIDE ASSOCIATIONS OF SCHIZOPHRENIA POLYGENIC RISK
por: Cao, Hengyi, et al.
Publicado: (2020)

O4.6. REAL-TIME FMRI NEUROFEEDBACK FOR TREATMENT REFRACTORY HALLUCINATIONS IN SCHIZOPHRENIA
Publicado: (2020)

O2.1. LOCAL AND LONG-RANGE CONNECTIVITY PATTERNS OF AUDITORY PERCEPTUAL DISTURBANCE IN SCHIZOPHRENIA
por: Hare, Stephanie, et al.
Publicado: (2020)

O6.2. A NETWORK FOR COGNITIVE, MOTOR, AND PSYCHOPATHOLOGICAL ALTERATIONS IN SCHIZOPHRENIA SPECTRUM DISORDERS
por: Moura, Bernardo, et al.
Publicado: (2020)

O5.5. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: MULTI-MODAL PET AND FMRI FINDINGS
por: Howes, Oliver, et al.
Publicado: (2020)

O1.4. HOW THE MOST CITED RESEARCH ARTICLES ABOUT SCHIZOPHRENIA IN 2018 DEPICT THE DISEASE?
por: Tonsig, Gabriela, et al.
Publicado: (2020)

O5.1. STRIATAL DOPAMINE AND REDUCED REWARD PREDICTION ERROR SIGNALING IN UNMEDICATED SCHIZOPHRENIA PATIENTS
por: Katthagen, Teresa, et al.
Publicado: (2020)

O3.1. CLUSTER ANALYSIS FINDS THREE CLINICALLY-RELEVANT SUBGROUPS OF TRAIT EMOTIONAL EXPERIENCE IN SCHIZOPHRENIA OUTPATIENTS
por: Cowan, Henry, et al.
Publicado: (2020)

O11.5. INCREASED INFLAMMATION AND MACROPHAGE INFILTRATION IS ASSOCIATED WITH ALTERED SUBEPENDYMAL ZONE NEUROGENESIS IN SCHIZOPHRENIA BUT NOT BIPOLAR DISORDER
por: North, Hayley, et al.
Publicado: (2020)

O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS
por: Chika Onwordi, Ellis, et al.
Publicado: (2020)

O2.5. CORTICAL PATTERNING OF ABNORMAL MORPHOMETRIC SIMILARITY IN PSYCHOSIS IS ASSOCIATED WITH BRAIN EXPRESSION OF SCHIZOPHRENIA-RELATED GENES
Publicado: (2020)

O11.1. MULTIPLE GENOMIC MEASURES OF SCHIZOPHRENIA RISK ARE RELATED TO CORTICAL THICKNESS IN TYPICALLY DEVELOPING YOUTH AND YOUNG ADULTS
por: Jalbrzikowski, Maria, et al.
Publicado: (2020)

O1.5. CLUSTERING-BASED BEHAVIOURAL PHENOTYPES OF INTRINSIC MOTIVATION IN SCHIZOPHRENIA DETERMINED USING OBJECTIVELY QUANTIFIED REAL-WORLD PERFORMANCE
por: Siddiqui, Ishraq, et al.
Publicado: (2020)

O8.1. ASSOCIATION BETWEEN GENETIC AND ENVIRONMENTAL RISK FOR SCHIZOPHRENIA DURING UPBRINGING: FINDINGS FROM A LONGITUDINAL COHORT STUDY
por: Newbury, Joanne, et al.
Publicado: (2020)

O6.3. ASSOCIATIONS BETWEEN COGNITIVE FUNCTION AND CORTICAL LEVELS OF GLUTAMATE AND GABA IN ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS
por: Bojesen, Kirsten, et al.
Publicado: (2020)

O1.6. AFFECTIVE DETERMINANTS OF LIFE-SPACE THROUGH GPS AND ECOLOGICAL MOMENTARY ASSESSMENT IN SCHIZOPHRENIA: WHAT GETS PEOPLE OUT OF THE HOUSE?
por: Parrish, Emma, et al.
Publicado: (2020)

O4.3. SHARED AND DIFFERENTIAL NEUROCOGNITIVE EFFECTS COMPARING HIGH-INTENSITY INTERVAL TRAINING AND ACTIVE VIDEO-GAMING IN SCHIZOPHRENIA – RESULTS FROM AN RCT
por: Bang-Kittilsen, Gry, et al.
Publicado: (2020)

O8.2. VALIDATION OF A COMPUTERIZED ADAPTIVE TESTING TOOL FOR PSYCHOSIS: THE CAT-PSYCHOSIS BATTERY
por: Guinart, Daniel, et al.
Publicado: (2020)

O10.5. CLINICAL HIGH RISK (CHR) CRITERIA IN CHILDREN AND ADOLESCENTS NOT SUSPECTED TO DEVELOP PSYCHOSIS: NO TRANSDIAGNOSTIC SEVERITY MARKER OF MENTAL HEALTH PROBLEMS
por: Schultze-Lutter, Frauke, et al.
Publicado: (2020)

O1.1. ETRo: EVALUATION OF THE TREATMENT APPROACH “ROBIN” (STANDARDIZED MANUAL AND SMARTPHONE APP) FOR ADOLESCENTS WITH CLINICAL HIGH RISK FOR DEVELOPING A PSYCHOTIC DISORDER
por: Traber-Walker, Nina, et al.
Publicado: (2020)

O6.5. JUMPING TO CONCLUSIONS ABOUT DECISION NOISE? A COMPUTATIONAL ANALYSIS OF THE RELATIONSHIP BETWEEN BELIEF UPDATING AND PSYCHOTIC SYMPTOMS IN A LARGE UK BIRTH COHORT
por: Croft, Jazz, et al.
Publicado: (2020)

mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge
por: Ben-Zeev, Dror, et al.
Publicado: (2016)

Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
por: Correll, Christoph U, et al.
Publicado: (2020)

O11.6. THE ROLE OF SERUM GLUTAMATE AND ASPARTATE AS MARKERS FOR CLOZAPINE RESPONSE AND IN THE MECHANISM OF ACTION – DATA FROM HUMAN AND ANIMAL MODEL STUDIES
Publicado: (2020)

O9.4. RELATIONSHIPS BETWEEN AGE AT ONSET OF PSYCHOTIC SYMPTOMS AND POOR RESPONSE TO ANTIPSYCHOTICS IN A SAMPLE OF TRS/NON-TRS PATIENTS
por: Iasevoli, Felice, et al.
Publicado: (2020)

O7.1. ASSOCIATION BETWEEN PATTERNS OF COMORBID MENTAL DISORDERS AND MORTALITY-RELATED ESTIMATES. A NATIONWIDE, REGISTER-BASED COHORT STUDY BASED ON 7.5 MILLION INDIVIDUALS LIVING IN DENMARK
por: Plana-Ripoll, Oleguer, et al.
Publicado: (2020)

O3.6. PREVALENCE OF AND RECOVERY FROM COMMON MENTAL DISORDERS INCLUDING PSYCHOTIC EXPERIENCES
por: Perez, Jesus, et al.
Publicado: (2020)

O7.5. STANDARDIZED MORTALITY RATIOS IN EARLY- AND ADULT ONSET FOR THREE DISORDERS
por: Lammers Vernal, Ditte, et al.
Publicado: (2020)

O5.6. ADVANCED DIFFUSION IMAGING IN PSYCHOSIS RISK: A CROSS-SECTIONAL AND LONGITUDINAL STUDY OF WHITE MATTER DEVELOPMENT
por: Di Biase, Maria, et al.
Publicado: (2020)

O6.4. ASSOCIATION BETWEEN CLUSTERS OF FORMAL THOUGHT DISORDERS SEVERITY AND NEUROCOGNITIVE AND FUNCTIONAL OUTCOME INDICES IN THE EARLY STAGES OF PSYCHOSIS – RESULTS FROM THE PRONIA COHORT
por: Öztürk, Ömer Faruk, et al.
Publicado: (2020)

O10.6. ANTERIOR VERSUS POSTERIOR HIPPOCAMPUS WITHIN PSYCHOSIS: A BSNIP STUDY
por: del Re, Elisabetta C, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_398840rvnspjj8lmjk9mpcklbb